血清IL-22在肾透明细胞癌患者预后分析中的应用价值

目的:研究IL-22在肾透明细胞癌（clear cell renal cell carcinoma，ccRCC）患者血清中的表达情况、临床意义及其在患者预后分析中的应用价值。方法:收集168例ccRCC患者的血清，同时以30例健康志愿者血清作为对照。采用ELISA法检测两组对象血清IL-22的表达水平。生存分析探讨IL-22表达水平与患者预后情况的关系。Cox比例风险模型分析影响患者生存时间的危险因素。结果:ccRCC患者血清中的IL-22水平明显高于健康志愿者。对ccRCC患者随访5~63个月，平均（45±12.4）个月，IL-22高水平组的无进展生存率及总体生存率明显低于低水平组。多因素分析结果表明，血清IL-22表达水平、肿瘤直径、肿瘤分化程度及肿瘤TNM分期是影响ccRCC患者生存期的独立危险因素。结论:ccRCC患者血清IL-22表达水平偏高，且IL-22高水平表达患者预后较差。血清IL-22表达水平在ccRCC患者的预后判断中具有较好的应用价值。

The value of IL -22 on the prognostic evaluation of clear cell renal cell carcinoma

Objective:To investigate the level of serum IL -22 in ccRCC tissues and to evaluate its relationship with ccRCC pathological features and prognosis.Methods:The expression of serum IL -22 in 168 ccRCC patients and 30 healthy donors was tested by ELISA.Survival analysis and Cox proportional hazard model were used in test. Results:The expression of serum IL -22 was significantly higher in ccRCC patients than that in healthy donors.The profession -free survival and overall survival rate in high expression group were lower than those in the low expression group.Conclusion:The level of serum IL -22 in ccRCC patients is high and the high expression group has a worse prognosis.The expression level of serum IL -22 relates to the clinical pathological feature of tumor and can be used as an independent predictor for ccRCC patients.